Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
Open Access
- 23 February 2022
- journal article
- research article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (3) , 66
Abstract
Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomyopathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administration of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care.Keywords
This publication has 44 references indexed in Scilit:
- Cancer Therapy–Related Cardiac Dysfunction and Heart FailureCirculation: Heart Failure, 2016
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyThe Lancet Oncology, 2016
- Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitorsCritical Reviews in Oncology/Hematology, 2015
- Trastuzumab-containing regimens for metastatic breast cancerCochrane Database of Systematic Reviews, 2014
- Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant HemopathiesJACC, 2013
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Cancer treatment and survivorship statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- The Vulnerability of the Heart As a Pluricellular Paracrine OrganCirculation Research, 2010
- Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent PathwaysJournal of Biological Chemistry, 2009
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007